Thought Leadership
The Asia Pacific Center of Excellence has a deep knowledge of the nuanced differences within each market of the region, and understand when it is beneficial or necessary to gather insights from stakeholders beyond payers and physicians to answer our client’s questions.
Showing 5 of 9 posts
January 27, 2021 | Infographics
China’s 2020 NRDL – Standout Features from the Finalized List
There have been several notable standout features in the 2020 NRDL including an update which saw manufacturer applications allowed for the first time compared to prior updates.
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia
A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations
A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.
September 7, 2020 | Research posters
ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy
A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.
June 2, 2020 | Blogs
2019 NRDL: Insights for Future Pricing Negotiations in China
The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.